logo.png
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
April 03, 2024 07:00 ET | Arch Biopartners
TORONTO, April 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Anesthesia Clinical Trials Unit (ACTU), an...
MaRS Innovation Laun
MaRS Innovation Launches New Drug Discovery Program Targeting Rare and Disabling Developmental Disorder
July 15, 2019 07:00 ET | MaRS Innovation
Toronto, ON, July 15, 2019 (GLOBE NEWSWIRE) -- MaRS Innovation announced today that it is partnering with Dr. James Eubanks at the University Health Network (UHN) to develop a new treatment for Rett...
enwave-energy-corp.jpg
Enwave and University Health Network team up to control energy costs, improve reliability and support patient care
March 20, 2019 10:18 ET | Enwave Energy Corporation
TORONTO, March 20, 2019 (GLOBE NEWSWIRE) -- Enwave Energy Corporation (Enwave) is working with the University Health Network (UHN) to connect the Princess Margaret Cancer Centre to Enwave’s Deep...
LAB150 awards its second drug discovery project from Canada’s largest research based Hospital, The University Health Network (UHN)
October 04, 2018 08:00 ET | MaRS Innovation
Toronto, ON, Oct. 04, 2018 (GLOBE NEWSWIRE) -- MaRS Innovation announced today the second project to be developed under their LAB150 partnership with Evotec.   The project aims to develop a...